ACM
TARS icon

ADAR1 Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

ADAR1 Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,900
Closed -$1.18M – 295
2024
Q3 		$852K Buy
+25,900
New +$728K 0.14% 87

Other funds holding TARS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

ADAR1 Capital Management's TARS Position: Q4 2024 in Review

ADAR1 Capital Management sold out of Tarsus Pharmaceuticals (TARS) in Q4 2024, closing a stake of 25,900 shares — an estimated $1.18M sold.

ADAR1 Capital Management first reported a position in TARS in Q3 2024 and held it in 1 quarter. The position peaked at $852K in Q3 2024. 195 funds tracked by Wall St. Rank hold TARS as of Q4 2024.

  • ADAR1 Capital Management reported no remaining Tarsus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • ADAR1 Capital Management sold 25,900 Tarsus Pharmaceuticals shares in Q4 2024, an estimated $1.18M.
  • ADAR1 Capital Management first reported a position in Tarsus Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • ADAR1 Capital Management's Tarsus Pharmaceuticals position peaked at $852K in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2024.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.